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Introduction.There are fewdata regarding the tolerability, safety, or efficacy of antenatal atazanavir.We report our clinical experience
of atazanavir use in pregnancy. Methods. A retrospective medical records review of atazanavir-exposed pregnancies in 12 London
centres between 2004 and 2010. Results. There were 145 pregnancies in 135 women: 89 conceived whilst taking atazanavir-based
combination antiretroviral therapy (cART), “preconception” atazanavir exposure; 27 started atazanavir-based cART as “first-
line” during the pregnancy; and 29 “switched” to an atazanavir-based regimen from another cART regimen during pregnancy.
Gastrointestinal intolerance requiring atazanavir cessation occurred in five pregnancies. Self-limiting, new-onset transaminitis
was most common in first-line use, occurring in 11.0%. Atazanavir was commenced in five switch pregnancies in the presence
of transaminitis, two of which discontinued atazanavir with persistent transaminitis. HIV-VL < 50 copies/mL was achieved in
89.3% preconception, 56.5% first-line, and 72.0% switch exposures. Singleton preterm delivery (<37 weeks) occurred in 11.7%
preconception, 9.1% first-line, and 7.7% switch exposures. Four infants required phototherapy. There was one mother-to-child
transmission in a poorly adherent woman. Conclusions. These data suggest that atazanavir is well tolerated and can be safely
prescribed as a component of combination antiretroviral therapy in pregnancy.
1. Introduction
Atazanavir has been licensed for the treatment of HIV infec-
tion in nonpregnant adults in the UK since 2004. Off-license
antenatal use is increasing; however, safety and efficacy data
in this setting are lacking.
Atazanavir is a protease inhibitor (PI), a drug class which
has been associated in some reports with increased risk
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of preterm delivery (PTD) and gestational diabetes [1–6].
Inhibition of uridine diphosphate-glucuronosyl transferase
(UGT) 1A1 enzyme by atazanavir results in an unconjugated
hyperbilirubinemia often presenting as jaundice; some have
questioned whether this can result in increased neonatal
hyperbilirubinemia [7, 8]. The optimum dosing regimen
for atazanavir in pregnancy is also debated. The standard
atazanavir-containing regimen consists of atazanavir 300mg
given with ritonavir 100mg once daily (QD) in combina-
tion with two nucleos(t)ide reverse transcriptase inhibitors
(NRTIs); ritonavir boosts plasma atazanavir concentrations
through cytochrome P450 inhibition. Atazanavir can be
administered without ritonavir at an increased dose; however
this is not recommended in pregnancy. Some authors advise
increasing the atazanavir dose to 400mg QD as both coad-
ministration of tenofovir [9, 10] and antenatal physiological
changes are associated with reduced total plasma atazanavir
concentrations [10].
Safety concerns prevent the inclusion of pregnant women
in clinical trials; therefore, observational data are required to
assess the safety and efficacy of novel agents antenatally. The
aim of this study is to report maternal and neonatal outcomes
following antenatal atazanavir exposure in the routine clinical
setting.
2. Methods
This was a retrospective medical records review of pregnan-
cies exposed to atazanavir and completing 12 weeks’ gesta-
tion across 12 participating London HIV specialist centres
between March 1, 2004, and December 1, 2010. Data were
abstracted from medical records on demographics; medi-
cal history; symptoms; CD4+ T-lymphocyte counts (CD4
counts); HIV viral load (VL); treatment; adherence; mater-
nal biochemistry; pregnancy and infant outcomes; neonatal
bilirubin; and infant HIV infection status.
The indication for atazanavir prescriptionwas categorised
for each pregnancy as “preconception,” if they were already
taking an atazanavir-containing regimen at the time of last
menstrual period (LMP); “switch,” if atazanavir was com-
menced during this pregnancy in a woman already taking
combination antiretroviral therapy (cART); “first-line,” if a
first-line atazanavir-based regimen was initiated after the
LMP. The “switch” group included women conceiving on,
or initiating during this pregnancy, a non-atazanavir-based
cART regimen. Women were classified as discontinuing
atazanavir if a clinical decision was made to discontinue
atazanavir prescription prior to the end of pregnancy.
In the UK, maternal HIV infection is diagnosed in accor-
dance with national guidelines, by detection of HIV-specific
antibodies using a commercial enzyme-linked immunoassay
(EIA). The initial reactive assay is confirmed by a further,
different, and type-specific EIA. The diagnosis of HIV infec-
tion is reconfirmed on a separate sample taken at a different
time point [11]. Women testing positive for HIV 2 antibodies
were excluded from the analysis. Hepatitis B virus (HBV)
or hepatitis C virus (HCV) coinfection was diagnosed by
the detection of antigen (HBV) or the respective nucleic
acids at any point during the pregnancy. Hepatotoxicity was
defined according to the AIDS Clinical Trial Group (ACTG)
grading of grade 1–4 transaminitis [12]. Plasma HIV-1 RNA
<50 copies/mL was classified as “undetectable” and ≥50
copies/mL as “detectable.”
Mode of delivery was classified as vaginal delivery (VD),
planned prelabour prerupture of membranes Caesarean sec-
tion (PLCS), or emergency Caesarean section (ECS), the
latter including all unplanned Caesarean sections. Analysis of
birthweight and gestational age at delivery included data only
from singleton deliveries. Deliveries at <37 weeks’ completed
gestation were classified as spontaneous preterm if labour
occurred spontaneously or iatrogenic preterm in the event
of induced delivery or PLCS. Neonates weighing <2500 g
were classified as having low birth weight (LBW).Mother-to-
child transmission was identified through testing infants for
HIV proviral DNA at birth and at >3 months of life, as per
the British HIV Association Guidelines [13]. Peak neonatal
bilirubin concentrations measured within the first 14 days
of birth were recorded. Neonatal hyperbilirubinemia was
classified as per the ACTG grading [14]. Use of phototherapy
was recorded. Congenital (birth) defects as defined by the
European Surveillance of Congenital Abnormalities (EURO-
CAT) [15] were reported if identified antenatally through
screening programmes or during the neonatal examination.
Anonymised data were entered into a specifically
designed Access database. Once cleaned the data were
exported to STATA v12 for statistical analyses. Quantitative
data with normal distribution are presented as means with
95% confidence intervals (CI) while non normal data are
presented as medians with interquartile range (IQR). For the
purpose of analysis each pregnancy was treated as a case. A
logistic regression model was used to assess the strength of
associations between different exposures and HIV-VL <50
copies/mL at delivery both in a univariate analysis and after
adjustment forHIV-VL at the first antenatal visit andwhether
atazanavir had been prescribed preconception, first-line,
or switch. The following methods were used to account for
the correlation caused by multiple pregnancies occurring
in the same woman: robust standard errors and generalised
estimating equations (GEE) with an exchangeable correlation
matrix to model clustered data. All 𝑃 values presented are
two-sided and generated by Wald-type testing.
The use of anonymised clinical data collected as part of
routine care for this evaluation was conducted in accordance
with the UK National Research Ethics Service (NRES) guid-
ance.
3. Results
There were 145 pregnancies in 135 women. All were HIV-
1 positive. None were HIV-2 positive. Median age at the
first antenatal appointment was 32 years (IQR 28–37 years).
Recorded ethnicities were Black-African, 110 (75.9%); Black-
Caribbean, 10 (6.9%); and White, 8 (5.5%). HIV trans-
mission risks were heterosexual intercourse, 136 (93.8%);
injecting drug use, 5 (3.4%); mother-to-child-transmission,
3 (2.1%); and blood transfusion, 1 (0.7%). Seven pregnancies
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Table 1: Birth outcome data for pregnancies exposed to an atazanavir (ATV) containing regimen. Data are presented based on the indication
for atazanavir use.
Indication for atazanavir use∗
Preconception First-line Switch
Total pregnancies∗∗ 𝑛‡ 89 27 29
ATV discontinued 𝑛, %(95% CI)‡‡
5, 5.6%
(1.8–12.6%)
3, 11.1%
(2.4–29.1%)
3, 10.3%
(2.2–27.4%)
Gastrointestinal side
effects∗∗∗
𝑛, %
(95% CI)
23, 25.8%
(16.5–35.1%)
15, 55.6%
(35.5–75.6%)
10, 34.5%
(16.1–52.9%)
New-onset
transaminitis†
𝑛, %
(95% CI)
1, 1.1%
(0.02%–6.1%)
3, 11.0%
(2.4–29.1%)
0††, 0%
(0–14.2%)
Singleton deliveries††† 𝑛, %(95% CI)
80, 97.6%
(91.5–99.7%)
23, 95.8%
(78.9–99.9%)
26, 100%
(86.8–100%)
Twin deliveries††† 𝑛, %(95% CI)
2, 2.4%
(0.3–8.5%)
1, 4.2%
(0.1–21.1%)
0
(0–13.2%)
Gestation <37 weeks§ 𝑛, %(95% CI)
9, 11.7%
(5.5–21.0%)
2, 9.1%
(1.1–29.2%)
2, 7.7%
(1.0–25.1%)
Birth weight (grams)§ Median(IQR) 𝑁
‡‡‡
= 65
3160
(2870–3360) 𝑁 = 21
3030
(2720–3255) 𝑁 = 23
3030
(2670–3480)
Low birth weight
(<2500 grams)§
𝑛, %
(95% CI)
6, 9.2%
(3.5–19.0%)
3, 14.3%
(3.0–36.3%)
3, 13.0%
(2.7–33.6%)
Neonatal bilirubin
(𝜇mol/litre)
Median
(IQR)§§ 𝑁 = 54
70.5
(45.0–107.0) 𝑁 = 16
76
(54.3–112.3) 𝑁 = 20
70.5
(49.8–88.8)
HIV viral load <50
(copies/mL)
𝑛, %
(95% CI)
74, 89.3%
(80.4–94.9%)
23, 56.5%
(34.8–76.0%)
25, 72.0%
(49.7–87.0%)
∗Indication for ATV use: “preconception,” if already taking an atazanavir-containing regimen at the time of last menstrual period (LMP); “switch,” if atazanavir
was commenced during this pregnancy in a woman already taking combination antiretroviral therapy (cART); “first-line,” if a first-line atazanavir-based
regimen was initiated after the LMP.
∗∗Total pregnancies: number of pregnancies with data available for each of the listed outcomes.
∗∗∗Gastrointestinal side effects: nausea, vomiting, or diarrhoea.
†Transaminitis: AIDS Clinical Trial Group grade 1–4 transaminitis.
††Transaminitis in the “switch” exposure group presented for 24 women with normal transaminase levels at the time of switch.
†††
𝑛 refers to the number of live singleton/twin births in women who continued atazanavir until the time of delivery. % refers to the proportion of live births
that were singleton or twin respectively.
‡
𝑛: the number of events.
‡‡95% CI: 95% confidence interval calculated with robust standard errors.
‡‡‡
𝑁: the number of cases with data available.
§Birth weight and gestation data are only presented for singleton deliveries.
§§IQR: interquartile range.
(4.8%) occurred in women who were HBV-coinfected and
two (1.4%) in women who were HCV-coinfected. Median
maternal CD4 count at first antenatal appointment was 407
(range: 15–1161) cells/mm3. Categories of atazanavir exposure
were as follows: preconception, 89 (61.4%); switch, 29 (20%);
first-line, 27 (18.6%). There was no significant difference
in the demographic composition of the different atazanavir
exposure groups. Data on prevalence of nausea and vom-
iting, new-onset transaminitis, VL at delivery, PTD, birth
weight, neonatal jaundice, and events of mother-to-child-
transmission are summarised by exposure group in Table 1.
Key details are presented for each exposure group below.
3.1. Preconception Atazanavir. Of the 89 women who re-
ceived preconception atazanavir, five discontinued atazanavir
prior to delivery: two due to teratogenicity concerns, two due
to nausea, and one due to virological failure. Three women
were coinfected with HBV and two were coinfected with
HCV. There was one case of ACTG grade 2 transaminitis in
a woman coinfected with HCV; atazanavir was continued in
this case and the transaminitis resolved spontaneously prior
to delivery.
There were two intrauterine deaths: one at 14 weeks’
gestation associated with trisomy 21 (maternal age 39) and
one stillbirth at 27 weeks’ gestation, the cause of which is
unclear and no autopsy results are available. There were 82
live births amongst women who conceived on atazanavir (80
singleton and 2 twin deliveries), amongst which there were
two reported congenital abnormalities: one case of trisomy
21 with an associated atrial septal defect (maternal age 44)
and one severe congenital cardiac abnormality incompatible
with life (maternal age 38). There were no ACTG grade 2–4
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events of neonatal hyperbilirubinemia. Phototherapy was
used in one twin with haemolytic disease of the newborn
(neonatal bilirubin 194𝜇mol/litre). One infant, delivered by
ECS, was infected in utero, with HIV proviral DNA detected
at delivery and at age three months. Maternal adherence
to antiretroviral therapy during pregnancy had been poor
and HIV-VL at delivery was 1103 copies/mL. No other HIV
transmissions were reported. A negative HIV proviral DNA
result was available at delivery and at 3 months for 73 and 67
infants, respectively.
3.2. First-Line Atazanavir. Of the 27 women receiving first-
line atazanavir, three discontinued atazanavir prior to deliv-
ery: two for nausea and vomiting and one for abdominal
pain and gallstones. Nausea and vomiting were reported in
15 (55.6%; 95% CI 35.5–75.6%).
Two cases were coinfected with HBV; none were coin-
fected with HCV. All 27 women commencing first-line
atazanavir did so with normal baseline transaminase levels.
Spontaneously resolving transaminitis developed in 3 (11%)
cases (ACTG grade 2 in 2 cases who were not HBV/HCV-
coinfected and ACTG grade 4 in 1 case with HBV coinfec-
tion).
There were no intrauterine deaths or reports of congenital
abnormalities. Atazanavir was continued to delivery in 23
singleton and one twin pregnancies. There were no ACTG
grade 2–4 events of neonatal hyperbilirubinemia. Two single-
ton infants with comorbidities required phototherapy. These
infants had been diagnosed with polycythaemia neonatorum
(neonatal bilirubin 258𝜇mol/litre) and infant haemolytic
anaemia (neonatal bilirubin 109 𝜇mol/litre), respectively.The
median duration of antiretroviral treatment prior to delivery
was 16.8 weeks (range: 2.7–30.4 weeks). Overall, an unde-
tectable VL at delivery was achieved in 13/23 women who
were prescribed first-line atazanavir (56.5%, 95% CI 34.8–
76.0%). When categorised by the duration of ART exposure
prior to delivery, an undetectable viral load was achieved in
4/10 women who received <16 weeks cART (40.0%, 95% CI
10.2–63.5%) compared to 9/13 who received ≥16 weeks cART
(69.2%, 95% CI 36.5–89.8%). HIV proviral DNA results were
available for all 24 infants at delivery and for 19 singletons
at three months, with no reported cases of mother-to-child-
transmission.
3.3. Switch Exposure to Atazanavir. Of the 29 women who
switched to atazanavir, 13 had conceived on an alternative
regimen and 16 had commenced an alternative regimen dur-
ing the course of this pregnancy. Three women discontinued
atazanavir prior to delivery: one due to intolerance and two
due to transaminitis.
The commonest reason for switching to atazanavir was
symptomatic intolerance of the discontinued regimen: 21/29
switched because of gastrointestinal symptoms attributed to
antiretroviral therapy. Of the 20 who switched from another
PI, symptoms improved in 19 (95.0%, 95% CI 69.6–98.8%).
Ten of the 29 women (34.5%; 95% CI 16.1–52.9%) had new
or worsening of gastrointestinal side effects after switching to
atazanavir which was also discontinued in one pregnancy.
Two cases were coinfected with HBV; none were coin-
fected with HCV. Transaminase levels were normal at the
time of atazanavir switch in 24/29 cases; none of these
developed new-onset transaminitis (Table 1). In five cases
atazanavir was commenced in women with elevated base-
line transaminases. In two of these five cases, atazanavir
was discontinued due to persistent transaminitis; in both
cases women had switched to an atazanavir-based regimen
from a lopinavir-based regimen with grade 2 transaminitis,
following which atazanavir was switched to raltegravir with
subsequent resolution of transaminitis. Neither case was
coinfected withHBV orHCV. Atazanavir was continuedwith
resolution of transaminitis in three of these five cases, of
which two, who were both HBV-coinfected, had switched
from lopinavir-containing therapy because of nausea and
grade 3 transaminitis and one had switched from nevirapine-
containing therapy because of hypersensitivity and grade 1
transaminitis.
No intrauterine deaths or congenital abnormalities were
reported in this group. Excluding the three cases in which
atazanavir was discontinued, there were 26 live single-
ton deliveries. There were no ACTG grade 2–4 events of
neonatal hyperbilirubinemia. One infant with no recorded
comorbidities required phototherapy (neonatal bilirubin
194 𝜇mol/litre). HIV proviral DNA results were available for
24 infants at delivery and 22 infants at 3 months, with no
reported cases of mother-to-child transmission.
3.4. Atazanavir Dosing Regimens and Virological Suppression
at Delivery. Data on HIV-VL at delivery amongst women
prescribed different atazanavir dosing regimens are dis-
played in Table 2. Women who remained on atazanavir
300mg/ritonavir 100mg throughout pregnancy were most
likely to achieve an undetectableHIV-VL at delivery; however
there was no good evidence of an association between unde-
tectable VL at delivery and the atazanavir dosing regimen in
the univariate (𝑃 = 0.1) or multivariate analysis (𝑃 = 0.1)
after adjusting for atazanavir treatment group and HIV-VL at
the first antenatal visit.
4. Discussion
We present data on outcomes seen amongst women who
have been prescribed atazanavir in a routine clinical envi-
ronment. Overall atazanavir was well tolerated, with hepato-
toxicity necessitating treatment switch occurring only when
atazanavir was commenced on a background of existing
transaminitis. Neonatal hyperbilirubinemia requiring pho-
totherapy was uncommon and the only mother-to-child
transmission event was attributed to poor adherence.
Large HIV cohort studies such as The Antiretroviral
Pregnancy Register [16] and the National Study of HIV in
Pregnancy and Childhood [17] continue to report on many
antenatal outcomes including antiretroviral teratogenicity,
virological efficacy, mother-to-child transmission, and trends
in antenatal antiretroviral use. However, these studies do not
capture data on some clinically relevant queries such as drug
Infectious Diseases in Obstetrics and Gynecology 5
Table 2: Proportion of women achieving an HIV viral load <50 copies/mL by treatment regimen at time of delivery.
𝑛
∗
HIV viral load <50 copies/mL
%
(95% CI)
All regimens 122 80.3%(72.1–86.6%)
ATV 300/R throughout∗∗ 101 83.2%(74.3–89.4%)
ATV 400/R escalated∗∗∗ 11 72.7%(33.5–93.4%)
ATV 400 throughout† 7 50%(11.0–89.0%)
ATV >400‡ 2 100%(15.8–100%)
ATV 400 (reduced to 300/R)§ 1 100%(2.5–100%)
∗
𝑛: number of pregnancies in which women were taking the specified regimen at the time of delivery.
∗∗ATV 300/R throughout: women were prescribed atazanavir 300mg/ritonavir 100mg at all times when an atazanavir based regimen was prescribed in the
recorded pregnancy.
∗∗∗ATV 400/R escalated: women prescribed atazanavir 300mg/ritonavir 100mg initially; then dose increased to atazanavir 400mg/ritonavir 100mg in the
third trimester.
†ATV 400 throughout: women prescribed atazanavir 400mg without ritonavir throughout pregnancy.
‡ATV >400 two pregnancies, both occurring in the same woman, where a dose of atazanavir >400mg was prescribed without ritonavir boosting.
§ATV 400 (reduced to 300/R): women prescribed atazanavir 400mg without ritonavir at the start of pregnancy which was converted to atazanavir
300mg/ritonavir 100mg.
tolerability, toxicity, or optimum drug dosing. Our analysis
focuses on these questions.
Intolerance was the most common indication for switch-
ing to atazanavir following which symptoms resolved in
the majority. In the absence of a control group we cannot
conclude that symptom resolution was attributable to switch-
ing. Our findings do suggest, however, that atazanavir may
be a useful option to consider amongst women intolerant
of other regimens. This is in line with the findings of a
recently published observational analysis which suggests that
atazanavir-based therapy is comparable to lopinavir-based
therapy in terms of safety and efficacy [18].
These data do not support routine atazanavir dose
escalation in pregnancy, in keeping with another recent
report [19]. Despite most women remaining on atazanavir
300mg/ritonavir 100mg during the third trimester, the over-
all rate of complete HIV viral load suppression at delivery
and the rate of mother-to-child transmission amongst those
who conceived on atazanavir were comparable to those
reported in other cohorts [20–24]. A low percentage of
women who commenced first-line atazanavir achieved an
undetectable HIV viral load at delivery (56.5%); however
10/23 of this group had received less than 16 weeks of cART
prior to delivery, a shorter treatment duration than that
recommended by the British HIV Association [13].
The neonatal outcomes are reassuring in terms of PTD
and neonatal jaundice. The risk of PTD compares favourably
to rates reported with other cART- and specifically PI-
exposed cohorts [2, 25–27]. The need for phototherapy
(4/120) was much lower than that reported in another obser-
vational cohort where 5/23 neonates required phototherapy
[8]. However, our findings are in keeping with other pub-
lished data which support the theory that in utero exposure
to atazanavir does not exacerbate physiological jaundice [28].
This may be attributable to poor transplacental atazanavir
transfer [29].
The main limitations to this study are selection bias and
information bias: due to the limited experience of atazanavir
in pregnancy, the women in our study partly represent a
cohort that was intolerant of othermore established regimens
(the switch cohort), whilst the indications for commencing
first-line atazanavir were not recorded. As with all medical
records reviews, data collection was retrospective and depen-
dant on accuracy and availability of clinical record keeping.
This has resulted in large amount of missing data which
could introduce bias into the analysis, especially affecting
infant outcomes. The follow-up of in utero exposed infants is
limited to neonatal examination and postnatal HIV testing;
we therefore cannot comment on whether in utero atazanavir
exposure is associated with longer-term risks to the infant.
In addition, despite the size of the overall cohort, the small
sample size of subgroups limits the precision of estimates in
subgroup analysis.
5. Conclusion
This is, to our knowledge, the largest case series to date
of atazanavir use in pregnancy. In summary we found that
atazanavir as part of antenatal cART appears safe and well
tolerated. Data onHIV viral load at delivery and transmission
have not raised any concerns regarding efficacy for women
conceiving on or switching to atazanavir-based cART. The
overall risk of mother-to-child transmission is similar to that
reported in other cohorts. Further data are required to assess
whether initiation of atazanavir-based cART as a first line
regimen during pregnancy has a similar efficacy in achieving
6 Infectious Diseases in Obstetrics and Gynecology
virological suppression by the time of delivery in comparison
with other antiretroviral regimens.
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